What Fueled The Previous Growth In The ACE Inhibitors Market?
The ace inhibitors market has seen considerable growth due to a variety of factors.
•The market for ACE inhibitors has seen consistent expansion in the past few years. It is projected to increase from $7.15 billion in 2024 to $7.48 billion in 2025, with a compound annual growth rate (CAGR) of 4.6%.
The previous growth can be traced back to factors such as a surge in cases of cardiovascular disease, an aging population, clinical efficiency and safety standards, prevalence of diabetes, and regulatory approval and guidelines.
What Is The Expected Growth In The ACE Inhibitors Market Size?
The ace inhibitors market is expected to maintain its strong growth trajectory in upcoming years.
• Expected to see robust growth in the forthcoming years, the market size of ACE inhibitors is projected to expand to "$9.6 billion in 2029 at a compound annual growth rate (CAGR) of 6.4%.
The growth during the predicted period can be linked to the escalating global impact of cardiovascular diseases, the widening of treatment guidelines for hypertension, advancements in combination treatments, attention to heart failure management, and the rise in healthcare awareness and access. Key trends in the forecast period encompass focus on kidney protection, a preference for renin-angiotensin system inhibitors, the competition in the generic market and pricing pressures, patient-driven approaches in healthcare, as well as regulatory changes and safety considerations.
What Main Forces Are Fueling Expansion In The ACE Inhibitors Market?
The ACE inhibitors market is expected to grow due to the rising prevalence of hypertension disorders. Hypertension, or high blood pressure, is a situation where there's heightened pressure in the blood vessels. Angiotensin-converting enzyme inhibitors, commonly known as ACE inhibitors, are a class of drugs used to manage and control hypertension. They work by relaxing blood vessels, thereby lowering blood pressure and increasing blood circulation. For instance, the World Health Organization, a specialized agency of the United Nations based in Switzerland, reported in March 2023 that about 1.28 billion adults aged 30 and 79 globally were suffering from hypertension, the majority of whom live in low- and middle-income countries. Over the past three decades, the number of people in the 30-79 age bracket affected by hypertension has risen by 650 million. An alarming 46% of adults with hypertension don't even realize they have the condition, due to lack of diagnosis. This escalating rate of undiagnosed hypertension, paired with the overall increase in hypertensive patients, is expected to fuel the expansion of the ACE inhibitors market.
What Are The Primary Segments In The Global ACE Inhibitors Market?
The ACE inhibitors market covered in this report is segmented –
1) By Type: Sulfhydryl-containing Agents, Dicarboxylate-containing Agents, Phosphonate-containing Agents
2) By Drug: Ramipril, Enalapril, Benazepril, Fosinopril, Captopril, Moexipril, Other Drugs
3) By Dosage Form: Oral Tablets, Oral Solutions
4) By Application: Heart Failure, Chronic Kidney Disease, Hypertension, Diabetes, Heart Attack, Other Applications
5) By End-Users: Hospitals, Online Drug Stores, Other End-Users
Subsegments:
1) By Sulfhydryl-Containing Agents: Captopril, Zofenopril
2) By Dicarboxylate-Containing Agents: Enalapril, Lisinopril, Ramipril, Quinapril, Benazepril, Perindopril
3) By Phosphonate-Containing Agents: Fosinopril
Pre-Book The ACE Inhibitors Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Key Trends Are Driving Changes In The ACE Inhibitors Market?
Product innovation is becoming an increasingly recognized trend in the ACE inhibitors market. A majority of corporations working in this sector are putting a strong emphasis on the development of novel products, aimed at solidifying their market presence and achieving a competitive edge. To illustrate, Travere Therapeutics, a biopharmaceutical firm based in the U.S., received FDA approval for FILSPARI (sparsentan) in February 2023. This unprecedented non-immunosuppressive treatment is intended for use in patients with IgA nephropathy (IgAN). The therapeutic protocol includes systemic glucocorticoids, angiotensin-converting enzyme (ACE) inhibitors, and antihypertensive drugs, one of which is angiotensin-receptor blockers (ARBs). FILSPARI stands out as the sole non-immunosuppressive therapy approved and is a once-daily oral medication designed for adult patients with primary IgAN who are prone to fast progression of the disease and usually present with a UPCR of under 1.5 g/g and proteinuria.
Who Are the Key Players in the ACE Inhibitors Market?
Major companies operating in the ACE inhibitors market include:
• Pfizer Inc.
• Novartis AG
• Johnson & Johnson Private Limited
• Merck KGaA
• Sanofi S.A.
• Bayer AG
• Teva Pharmaceutical Industries Ltd.
• Bristol-Myers Squibb Co.
• Takeda Pharmaceuticals Company
• Daiichi Sankyo Company Ltd.
• UCB Schwarz Pharma Inc.
• Endo International plc
• Sun Pharmaceutical Industries Ltd.
• Boehringer Ingelheim
• Bausch Health Companies Inc.
• Dr. Reddy's Laboratories
• Abbott Laboratories
• Eli Lilly and Company
• Cipla Limited
• GlaxoSmithKline plc
• Cadila Healthcare Limited
• AbbVie Inc.
• Sandoz Group AG
• Accord Healthcare Ltd.
• AstraZeneca plc
• Lupin Limited
• Macleods Pharmaceuticals Limited
• Zydus lifescience Ltd.
• Apotex Inc.
What Is The Most Dominant Region In The ACE Inhibitors Market?
North America was the largest region in the ACE inhibitors market in 2024.Asia-Pacific is expected to be the fastest-growing region in the global ACE inhibitors market report during the forecast period. The regions covered in the ace inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
